325 related articles for article (PubMed ID: 11864932)
1. Maximizing the natriuretic peptide system in experimental heart failure: subcutaneous brain natriuretic peptide and acute vasopeptidase inhibition.
Chen HH; Lainchbury JG; Harty GJ; Burnett JC
Circulation; 2002 Feb; 105(8):999-1003. PubMed ID: 11864932
[TBL] [Abstract][Full Text] [Related]
2. Differential actions of vasopeptidase inhibition versus angiotensin-converting enzyme inhibition on diuretic therapy in experimental congestive heart failure.
Cataliotti A; Boerrigter G; Chen HH; Jougasaki M; Costello LC; Tsuruda T; Lee SC; Malatino LS; Burnett JC
Circulation; 2002 Feb; 105(5):639-44. PubMed ID: 11827932
[TBL] [Abstract][Full Text] [Related]
3. Endogenous natriuretic peptides participate in renal and humoral actions of acute vasopeptidase inhibition in experimental mild heart failure.
Chen HH; Lainchbury JG; Matsuda Y; Harty GJ; Burnett JC
Hypertension; 2001 Aug; 38(2):187-91. PubMed ID: 11509474
[TBL] [Abstract][Full Text] [Related]
4. Intact acute cardiorenal and humoral responsiveness following chronic subcutaneous administration of the cardiac peptide BNP in experimental heart failure.
Chen HH; Schirger JA; Cataliotti A; Burnett JC
Eur J Heart Fail; 2006 Nov; 8(7):681-6. PubMed ID: 16459135
[TBL] [Abstract][Full Text] [Related]
5. Maximizing the renal cyclic 3'-5'-guanosine monophosphate system with type V phosphodiesterase inhibition and exogenous natriuretic peptide: a novel strategy to improve renal function in experimental overt heart failure.
Chen HH; Huntley BK; Schirger JA; Cataliotti A; Burnett JC
J Am Soc Nephrol; 2006 Oct; 17(10):2742-7. PubMed ID: 16928803
[TBL] [Abstract][Full Text] [Related]
6. Antihypertrophic effects of combined inhibition of the renin-angiotensin system (RAS) and neutral endopeptidase (NEP) in progressive, tachycardia-induced experimental heart failure.
Birner C; Ulucan C; Bratfisch M; Götz T; Dietl A; Schweda F; Riegger GA; Luchner A
Naunyn Schmiedebergs Arch Pharmacol; 2012 Nov; 385(11):1117-25. PubMed ID: 22895639
[TBL] [Abstract][Full Text] [Related]
7. Vasopeptidase inhibition: a new concept in blood pressure management.
Burnett JC
J Hypertens Suppl; 1999 Feb; 17(1):S37-43. PubMed ID: 10340842
[TBL] [Abstract][Full Text] [Related]
8. Equimolar doses of atrial and brain natriuretic peptides and urodilatin have differential renal actions in overt experimental heart failure.
Chen HH; Cataliotti A; Schirger JA; Martin FL; Burnett JC
Am J Physiol Regul Integr Comp Physiol; 2005 May; 288(5):R1093-7. PubMed ID: 15627648
[TBL] [Abstract][Full Text] [Related]
9. Beneficial renal and hemodynamic effects of omapatrilat in mild and severe heart failure.
Troughton RW; Rademaker MT; Powell JD; Yandle TG; Espiner EA; Frampton CM; Nicholls MG; Richards AM
Hypertension; 2000 Oct; 36(4):523-30. PubMed ID: 11040230
[TBL] [Abstract][Full Text] [Related]
10. Subcutaneous administration of brain natriuretic peptide in experimental heart failure.
Chen HH; Grantham JA; Schirger JA; Jougasaki M; Redfield MM; Burnett JC
J Am Coll Cardiol; 2000 Nov; 36(5):1706-12. PubMed ID: 11079680
[TBL] [Abstract][Full Text] [Related]
11. Brain natriuretic peptide enhances renal actions of furosemide and suppresses furosemide-induced aldosterone activation in experimental heart failure.
Cataliotti A; Boerrigter G; Costello-Boerrigter LC; Schirger JA; Tsuruda T; Heublein DM; Chen HH; Malatino LS; Burnett JC
Circulation; 2004 Apr; 109(13):1680-5. PubMed ID: 15023890
[TBL] [Abstract][Full Text] [Related]
12. Angiotensin inhibition potentiates the renal responses to neutral endopeptidase inhibition in dogs with congestive heart failure.
Margulies KB; Perrella MA; McKinley LJ; Burnett JC
J Clin Invest; 1991 Nov; 88(5):1636-42. PubMed ID: 1658047
[TBL] [Abstract][Full Text] [Related]
13. BNP: pathophysiological and potential therapeutic roles in acute congestive heart failure.
Grantham JA; Borgeson DD; Burnett JC
Am J Physiol; 1997 Apr; 272(4 Pt 2):R1077-83. PubMed ID: 9140004
[TBL] [Abstract][Full Text] [Related]
14. Subcutaneous administration of the cardiac hormone BNP in symptomatic human heart failure.
Chen HH; Redfield MM; Nordstrom LJ; Horton DP; Burnett JC
J Card Fail; 2004 Apr; 10(2):115-9. PubMed ID: 15101022
[TBL] [Abstract][Full Text] [Related]
15. Systemic hemodynamics, renal function and hormonal levels during inhibition of neutral endopeptidase 3.4.24.11 and angiotensin-converting enzyme in conscious dogs with pacing-induced heart failure.
Seymour AA; Asaad MM; Lanoce VM; Langenbacher KM; Fennell SA; Rogers WL
J Pharmacol Exp Ther; 1993 Aug; 266(2):872-83. PubMed ID: 8394922
[TBL] [Abstract][Full Text] [Related]
16. Natriuretic and antialdosterone actions of chronic oral NEP inhibition during progressive congestive heart failure.
Martin FL; Stevens TL; Cataliotti A; Schirger JA; Borgeson DD; Redfield MM; Luchner A; Burnett JC
Kidney Int; 2005 May; 67(5):1723-30. PubMed ID: 15840018
[TBL] [Abstract][Full Text] [Related]
17. Dual inhibition of angiotensin converting enzyme and neutral endopeptidase by omapatrilat in rat in vivo.
Bäcklund T; Palojoki E; Grönholm T; Eriksson A; Vuolteenaho O; Laine M; Tikkanen I
Pharmacol Res; 2001 Nov; 44(5):411-8. PubMed ID: 11712872
[TBL] [Abstract][Full Text] [Related]
18. Renal response to acute neutral endopeptidase inhibition in mild and severe experimental heart failure.
Chen HH; Schirger JA; Chau WL; Jougasaki M; Lisy O; Redfield MM; Barclay PT; Burnett JC
Circulation; 1999 Dec; 100(24):2443-8. PubMed ID: 10595958
[TBL] [Abstract][Full Text] [Related]
19. Role of the natriuretic peptides in the cardiorenal and humoral actions of omapatrilat: insights from experimental heart failure.
Chen HH; Cataliotti A; Burnett JC
Curr Hypertens Rep; 2001 Dec; 3 Suppl 2():S15-21. PubMed ID: 11716801
[TBL] [Abstract][Full Text] [Related]
20. Potentiation of natriuretic peptides by neutral endopeptidase inhibitors.
Seymour AA; Abboa-Offei BE; Smith PL; Mathers PD; Asaad MM; Rogers WL
Clin Exp Pharmacol Physiol; 1995 Jan; 22(1):63-9. PubMed ID: 7768036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
